ES2613700T3 - Inhibidores de la aldosa reductasa y usos de los mismos - Google Patents

Inhibidores de la aldosa reductasa y usos de los mismos Download PDF

Info

Publication number
ES2613700T3
ES2613700T3 ES11807523T ES11807523T ES2613700T3 ES 2613700 T3 ES2613700 T3 ES 2613700T3 ES 11807523 T ES11807523 T ES 11807523T ES 11807523 T ES11807523 T ES 11807523T ES 2613700 T3 ES2613700 T3 ES 2613700T3
Authority
ES
Spain
Prior art keywords
alkyl
formula
reductase inhibitors
aldose reductase
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11807523T
Other languages
English (en)
Inventor
Andrew Wasmuth
Donald W. Landry
Shi Xian Deng
Ravichandran Ramasamy
Ann Marie Schmidt
Banavara L. Mylari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Columbia University
Original Assignee
Columbia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Columbia University filed Critical Columbia University
Application granted granted Critical
Publication of ES2613700T3 publication Critical patent/ES2613700T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de fórmula (I)**Fórmula** en la que R1 es H, alquilo (C1-C6), hidroxialquilo (C1-C6) o amino (C1-C6)-alquilo; X1 es N o CR3; X2 es N o CR4; X3 es N o CR5; X4 es N o CR6; con la condición de que dos o tres de X1, X2, X3 o X4 sean N; Y es un enlace, C>=O, C>=S, C>=NH o C>=N-alquilo (C1-C4); Z es**Fórmula** A1 es NR11, O, S o CH2; A2 es N o CH; A3 es NR11, O o S; R3 a R10 son independientemente hidrógeno, halógeno, ciano, acilo, haloalquilo, haloalcoxi, haloalquiltio, trifluoroacetilo, alquilo (C1-C4), alcoxi (C1-C4), alquiltio (C1-C4), alquil (C1-C4)-sulfinilo o alquil (C1-C4)-sulfonilo; o dos de R3 a R6 o dos de R7 a R10 tomados conjuntamente son alquilen (C1-C4)-dioxi; y R11 es hidrógeno, alquilo C1-C4 o C(O)O-alquilo (C1-C4); o una sal o solvato farmacéuticamente aceptable del mismo.
ES11807523T 2010-07-16 2011-07-14 Inhibidores de la aldosa reductasa y usos de los mismos Active ES2613700T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36509810P 2010-07-16 2010-07-16
PCT/US2011/044038 WO2012009553A1 (en) 2010-07-16 2011-07-14 Aldose reductase inhibitors and uses thereof

Publications (1)

Publication Number Publication Date
ES2613700T3 true ES2613700T3 (es) 2017-05-25

Family

ID=45469805

Family Applications (3)

Application Number Title Priority Date Filing Date
ES11807523T Active ES2613700T3 (es) 2010-07-16 2011-07-14 Inhibidores de la aldosa reductasa y usos de los mismos
ES19194956T Active ES2931319T3 (es) 2010-07-16 2011-07-14 Inhibidores de aldosa reductasa y usos de los mismos
ES16187936T Active ES2769950T3 (es) 2010-07-16 2011-07-14 Inhibidores de la aldosa reductasa y usos de los mismos

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES19194956T Active ES2931319T3 (es) 2010-07-16 2011-07-14 Inhibidores de aldosa reductasa y usos de los mismos
ES16187936T Active ES2769950T3 (es) 2010-07-16 2011-07-14 Inhibidores de la aldosa reductasa y usos de los mismos

Country Status (15)

Country Link
EP (4) EP3597650B1 (es)
JP (4) JP5934206B2 (es)
CN (2) CN105732640B (es)
AU (1) AU2011279058B2 (es)
CA (1) CA2804640C (es)
DK (3) DK3597650T3 (es)
ES (3) ES2613700T3 (es)
HR (1) HRP20221430T1 (es)
HU (3) HUE031506T2 (es)
LT (1) LT3597650T (es)
PL (3) PL2593456T3 (es)
PT (1) PT3597650T (es)
RS (1) RS63796B1 (es)
SI (1) SI3597650T1 (es)
WO (1) WO2012009553A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
HUE031506T2 (en) * 2010-07-16 2017-07-28 Univ Columbia Aldose reductase inhibitors and their use
US12653825B2 (en) 2010-07-16 2026-06-16 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
US20140228319A1 (en) * 2013-02-13 2014-08-14 Banavara L. Mylari Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
ES2966094T3 (es) 2016-06-21 2024-04-18 Univ Columbia Compuestos 4-oxo-3,4-dihidrotieno[3,4-d]piridazina como inhibidores de la aldosa reductasa y métodos de uso de los mismos
IL272246B2 (en) 2017-07-28 2026-01-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
CN108101883B (zh) * 2018-01-31 2018-11-13 佳木斯大学附属第一医院 一种用于防治糖尿病视网膜病变的药物及其制备方法
WO2020167937A1 (en) * 2019-02-12 2020-08-20 Applied Therapeutics, Inc. Methods for treating cutaneous aging
CN113454084B (zh) * 2019-02-28 2023-08-29 石药集团中奇制药技术(石家庄)有限公司 醛糖还原酶抑制剂的盐及其制备方法和应用
CN113840825A (zh) 2019-04-01 2021-12-24 应用治疗公司 醛糖还原酶抑制剂
MX2021013511A (es) 2019-05-07 2022-02-23 Univ Miami Tratamiento y deteccion de neuropatias heredadas y trastornos asociados.
KR20230005944A (ko) 2020-05-01 2023-01-10 어플라이드 테라퓨틱스 인크. 소르비톨 데히드로게나제 결핍 치료를 위한 알도스 리덕타제 억제제
EP4211136B1 (en) * 2020-09-08 2025-08-20 Assia Chemical Industries Ltd. Solid state forms of at-001 and process for preparation thereof
CN116265463B (zh) * 2021-12-16 2025-08-05 石药集团中奇制药技术(石家庄)有限公司 一种醛糖还原酶抑制剂的晶型及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304A (en) 1847-09-25 Improvement in preparing and hardening raw hides
US557A (en) 1838-01-09 James macgregor
US4939140A (en) 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
CA1299178C (en) * 1985-11-07 1992-04-21 Banavara Lakshmana Mylari Heterocyclic oxophtalazinyl acetic acids
IL80475A (en) * 1985-11-07 1993-01-31 Pfizer Heterocyclic-substituted 4-oxo (or thio)-3h- phthalazinyl-acetic acid derivatives and pharmaceutical compositions containing them
WO1989006651A1 (en) * 1988-01-19 1989-07-27 Pfizer Inc. 1h-indazole-3-acetic acids as aldose reductase inhibitors
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
US4996204A (en) * 1989-05-11 1991-02-26 Pfizer Inc. Pyrido[2,3-d]pyridazinones as aldose reductase inhibitors
FR2647676A1 (fr) * 1989-06-05 1990-12-07 Union Pharma Scient Appl Nouveaux derives de pyridazinone, leurs procedes de preparation, medicaments les contenant, utiles notamment comme inhibiteurs de l'aldose reductase
FI922308L (fi) * 1989-12-15 1992-05-21 Pfizer Substituerade oxoftalazinylaettiks- syror och deras analoger.
JPH0495025A (ja) 1990-08-08 1992-03-27 Asahi Chem Ind Co Ltd アルドースリダクターゼ阻害剤
CN1200106A (zh) 1995-08-28 1998-11-25 美国家用产品公司 苯氧基乙酸类化合物用作醛糖还原酶抑制剂和抗高血糖药
AP2000001929A0 (en) * 1998-03-31 2000-09-30 Inst For Pharm Discovery Inc Substituted indolealkanoic acids.
EP0982306A3 (en) 1998-08-21 2000-07-05 Pfizer Products Inc. Polymorph of zopolrestat monohydrate
US6570013B2 (en) 2000-02-16 2003-05-27 Pfizer Inc Salts of zopolrestat
EP1469851B1 (en) 2002-01-23 2006-10-11 Eli Lilly And Company Melanocortin receptor agonists
HUE031506T2 (en) * 2010-07-16 2017-07-28 Univ Columbia Aldose reductase inhibitors and their use

Also Published As

Publication number Publication date
CN103052637A (zh) 2013-04-17
PL3597650T3 (pl) 2023-02-06
HUE060473T2 (hu) 2023-03-28
EP2593456B1 (en) 2016-11-30
JP6430670B2 (ja) 2018-11-28
CA2804640A1 (en) 2012-01-19
HUE031506T2 (en) 2017-07-28
HRP20221430T1 (hr) 2023-01-06
PL3192796T3 (pl) 2020-06-15
JP6306251B2 (ja) 2018-04-04
CA2804640C (en) 2018-09-25
SI3597650T1 (sl) 2023-02-28
DK3597650T3 (da) 2022-11-21
JP5934206B2 (ja) 2016-06-15
EP4124620A1 (en) 2023-02-01
JP2017200937A (ja) 2017-11-09
CN105732640A (zh) 2016-07-06
JP2013531062A (ja) 2013-08-01
HK1223925A1 (zh) 2017-08-11
JP6165897B2 (ja) 2017-07-19
DK2593456T3 (en) 2017-02-06
ES2769950T3 (es) 2020-06-29
EP3192796A1 (en) 2017-07-19
ES2931319T3 (es) 2022-12-28
AU2011279058B2 (en) 2015-10-01
JP2016106107A (ja) 2016-06-16
HUE047346T2 (hu) 2020-04-28
CN105732640B (zh) 2019-01-08
RS63796B1 (sr) 2022-12-30
WO2012009553A1 (en) 2012-01-19
JP2018087253A (ja) 2018-06-07
CN103052637B (zh) 2016-03-23
EP3597650B1 (en) 2022-09-07
EP2593456A1 (en) 2013-05-22
PT3597650T (pt) 2022-12-16
AU2011279058A1 (en) 2013-01-24
DK3192796T3 (da) 2019-12-09
LT3597650T (lt) 2022-12-12
EP2593456A4 (en) 2013-10-30
EP3597650A1 (en) 2020-01-22
PL2593456T3 (pl) 2017-06-30
EP3192796B1 (en) 2019-09-04

Similar Documents

Publication Publication Date Title
AR122069A2 (es) Inhibidores heterocíclicos de tirosina quinasa de bruton
EA201001013A1 (ru) Бис(сульфониламино)производные для применения в терапии
ECSP20027480A (es) Indolil alquil amino derivados sustituidos como nuevos inhibidores de la histona desacetilasa
EA201001359A1 (ru) Гетероциклические соединения в качестве ингибиторов cxcr2
SV2010003472A (es) Compuestos de pirazol
EA201101326A1 (ru) Ингибиторы антиапоптотических белков на основе нафталина
UY30141A1 (es) Nuevas isoindolonas potenciadoras de receptores metabotropicos de glutamato
CR11433A (es) Inhibidores de quinasa c-fms
UY30941A1 (es) Inhibidores de serina proteasas
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
CR11683A (es) Piridinas y pirazinas como inhibidores de p13k
CO6270320A2 (es) Derivados de piperidina utiles como antagonistas del receptor orexina
UY30584A1 (es) Inhibidor de quinasa
CY1110960T1 (el) ΠΑΡΑΓΩΓΑ ΤΗΣ 4-(2-ΑΜΙΝΟ-1-ΥΔΡΟΞΥΑΙΘΥΛ)ΦΑΙΝΟΛΗΣ ΩΣ ΑΓΩΝΙΣΤΕΣ ΤΟΥ β2 ΑΔΡΕΝΕΡΓΙΚΟΥ ΥΠΟΔΟΧΕΑ
ECSP088558A (es) Carbonilamino pirrolopirazoles, potentes inhibidores de quinasa
DK1931645T3 (da) N-(3-aminoquinoxalin-2-yl)-sulfonamidderivater og deres anvendelse som inhibitorer af phosphatidylinositol-3-kinase
AR094911A1 (es) SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR b2 ADRENÉRGICO ASÍ COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARÍNICO M₃
NI200800247A (es) Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmacéuticas que las contienen.
DK1761520T3 (da) Kinaseinhibitorer
EA201170456A1 (ru) Синергические комбинации макроциклического ингибитора вируса гепатита с и нуклеозида
HRP20221430T1 (hr) Inhibitori aldozoreduktaze i njihova uporaba
EA201171062A1 (ru) Алкиламидные соединения и их применение
HN2011000076A (es) Derivados de piridino-piridinonas, su preparacion.
AR072726A1 (es) Derivados de indol macrociclicos utiles como inhibidores del virus de la hepatitis c
AR082619A1 (es) Inhibidores del virus de la hepatitis c